Sarcoidosis is a chronic inflammatory disease in which clusters of immune cells, called granulomas, form in one or more organs. It most commonly affects the lungs and lymph nodes, but it can also involve the skin, eyes, heart, nervous system, and joints. About 20% of people with sarcoidosis experience spontaneous remission without any treatment, while roughly 58% have a good overall prognosis, meaning their disease either resolves on its own or stabilizes with therapy.
What Happens Inside the Body
In sarcoidosis, the immune system overreacts to a trigger that researchers still haven’t fully pinpointed. Certain white blood cells become hyperactive and cluster together, forming tiny clumps of inflamed tissue called noncaseating granulomas. These granulomas contain a mix of immune cells, including specialized cells that normally fight infection. The inflammation is driven by signaling molecules that amplify the immune response, creating a cycle where the body essentially attacks its own tissues without a clear infection to target.
These granulomas can form in almost any organ, but they tend to concentrate in the lungs and the lymph nodes in the chest. When enough granulomas accumulate, they can interfere with normal organ function. In the lungs, this means reduced ability to exchange oxygen. In the heart, it can disrupt the electrical signals that keep your heartbeat regular. In the eyes, it causes inflammation that can threaten vision.
Who Gets Sarcoidosis
Sarcoidosis can affect anyone, but it disproportionately impacts certain groups. It typically appears between ages 25 and 40, though higher disease burden has been observed in older adults as well. Black Americans develop sarcoidosis at significantly higher rates than white Americans and tend to have more severe disease. Scandinavians also have elevated rates compared to other European populations. The disease affects both sexes, though women are diagnosed slightly more often.
Causes and Triggers
No single cause of sarcoidosis has been identified, but the disease appears to result from a combination of genetic susceptibility and environmental exposure. Several genes on chromosome 6, part of the immune system’s recognition machinery, are strongly linked to disease risk. Some of these same genetic variants also influence which organs are affected. One variant is associated with eye inflammation, another with heart involvement, and yet another with Löfgren syndrome, an acute form of the disease.
On the environmental side, a large case-control study found modest increases in sarcoidosis risk among people exposed to insecticides, mold, and musty work environments. Agricultural workers showed higher rates than the general population. Certain inorganic substances, particularly beryllium and silica dust, can trigger a granulomatous response that closely mimics sarcoidosis. First responders at the World Trade Center disaster developed a similar lung condition after inhaling complex airborne particles. These findings suggest that inhaled environmental agents may set off the disease in people who are genetically predisposed.
Common Symptoms
Because sarcoidosis can affect so many organs, symptoms vary widely. The most common presentation involves the lungs and includes a persistent dry cough, shortness of breath, and chest discomfort. Fatigue is one of the most reported and most debilitating symptoms, often lingering even after other signs improve.
Skin involvement produces a range of changes, from raised reddish-purple bumps to flat discolored patches. Eye inflammation, or uveitis, causes redness, pain, blurred vision, and light sensitivity. The pattern of eye involvement differs by race: anterior uveitis (affecting the front of the eye) accounts for 70 to 75% of cases in Black patients, while posterior uveitis (affecting the back of the eye) makes up 65 to 83% of cases in white patients.
Joint pain, swollen lymph nodes, unexplained weight loss, and night sweats round out the typical symptom picture. Some people have no symptoms at all and discover the disease incidentally on a chest X-ray taken for another reason.
Löfgren Syndrome
Löfgren syndrome is an acute form of sarcoidosis with a distinct pattern: painful red nodules on the shins (erythema nodosum), swollen lymph nodes visible on chest imaging, fever, and joint inflammation that tends to migrate from one joint to another. The ankle is the most commonly affected joint, especially in men, though knees, wrists, and elbows can be involved. Despite its dramatic onset, Löfgren syndrome generally carries an excellent prognosis, with most cases resolving within months.
How Sarcoidosis Is Diagnosed
There is no single blood test or scan that confirms sarcoidosis. According to the American Thoracic Society, diagnosis rests on three pillars: a clinical presentation that fits the pattern, a tissue biopsy showing noncaseating granulomas, and the exclusion of other conditions that cause similar granulomas, such as tuberculosis, fungal infections, and certain cancers. Because no universally accepted cutoff exists for each of these criteria, the diagnosis is never considered completely airtight. It is, in practice, a diagnosis of exclusion supported by biopsy evidence.
Chest imaging, typically a CT scan, is usually the starting point. Blood work may show elevated calcium levels and elevated markers of inflammation. A biopsy, most commonly from the lungs or lymph nodes, provides the tissue sample needed to look for the characteristic granulomas.
Heart and Nervous System Involvement
Cardiac sarcoidosis deserves particular attention because it can cause life-threatening complications, including abnormal heart rhythms, heart failure, and sudden cardiac death. Warning signs include palpitations, lightheadedness, and fainting episodes. Current guidance recommends that all patients diagnosed with sarcoidosis in any organ undergo a baseline electrocardiogram and echocardiogram to screen for silent heart involvement. If those initial tests show abnormalities, or if cardiac symptoms develop, advanced imaging with cardiac MRI or a specialized PET scan can identify active inflammation in the heart muscle.
Neurosarcoidosis affects the brain, spinal cord, or peripheral nerves. It can cause facial drooping (similar to Bell’s palsy), headaches, vision changes, weakness, or numbness. Though less common than lung or skin involvement, neurological sarcoidosis tends to require more aggressive treatment and closer monitoring.
Treatment
Not everyone with sarcoidosis needs treatment. If the disease is mild and not causing significant symptoms or organ damage, doctors often take a watch-and-wait approach, monitoring with periodic imaging and blood work. Treatment is typically reserved for cases where sarcoidosis threatens organ function, produces debilitating symptoms, or involves the heart, eyes, or nervous system.
Corticosteroids are the first-line therapy and work by broadly suppressing the overactive immune response. Treatment usually begins at a moderate dose and is gradually tapered over months. The goal is to use the lowest effective dose for the shortest time, since long-term steroid use carries well-known side effects including weight gain, bone thinning, elevated blood sugar, and mood changes.
For patients who can’t tolerate steroids, don’t respond to them, or relapse when the dose is reduced, second-line options include immune-suppressing medications that allow for steroid tapering. These drugs take several weeks to reach full effect and require regular blood monitoring to check for side effects on the liver and blood counts. A third tier of treatment involves biologic medications that target specific inflammatory signaling molecules. These are typically reserved for refractory cases, particularly those involving the heart, nervous system, or severe skin disease.
Prognosis and Long-Term Outlook
The course of sarcoidosis is highly variable. In a study tracking 188 patients, outcomes broke down as follows: about 20% achieved spontaneous remission, 9% went into remission with treatment, 17% remained stable without progression, and 11% showed gradual regression. On the other end, roughly 20% experienced disease progression, 18% developed chronic disease requiring ongoing therapy, and about 4% had recurrences that needed retreatment.
Certain factors point toward a less favorable outcome. Involvement of multiple organs, Black race, older age at diagnosis, and the presence of cardiac or neurological disease all correlate with a more chronic course. Löfgren syndrome, by contrast, resolves in the vast majority of cases and rarely recurs. Pulmonary fibrosis, where scar tissue permanently replaces normal lung tissue, is the most serious long-term complication of lung sarcoidosis and the leading cause of sarcoidosis-related death.
Most people with sarcoidosis lead full, active lives, particularly when the disease is caught early and monitored appropriately. Even among those with chronic disease, treatment advances have improved quality of life substantially over the past two decades.